Sinopharm kicks off new listing rush with anchor orders
Sinopharm Group, one of the six Chinese companies that began final preparations for a Hong Kong listing this week, has lined up nine cornerstone investors for its $900m-$1bn initial public offering, in a sign of buyers' confidence in the region's equity markets.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts